Enterprise Value
135.9B
Cash
12.74B
Avg Qtr Burn
N/A
Short % of Float
0.00%
Insider Ownership
0.01%
Institutional Own.
10.52%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
ALTUVIIIO™ (Efanesoctocog alfa) Details Hemophilia | Approved Quarterly sales | |
TZIELD™ (PRV-031) (Teplizumab) Details Type 1 diabetes, Diabetes | Approved Quarterly sales | |
Nirsevimab Details Respiratory syncytial virus | PDUFA Approval decision | |
Sarclisa® Details Cancer, Multiple myeloma | Phase 3 Data readout | |
PRV-031 (Teplizumab) Details Type 1 diabetes, Diabetes | Phase 3 Data readout | |
Frexalimab Details Autoimmune disease, Multiple sclerosis | Phase 3 Initiation | |
Ordesekimab (PRV-015) (anti-IL-15) Details Celiac disease, Immune Disorders Big Mover™ Suspected Mover™ Susp. Mover™ | Phase 2b Data readout | |
PRV-3279 Details Systemic lupus erythematosus, Autoimmune disease | Phase 2a Data readout |